While breast cancer remains the most lethal malignancy amongst women across the world, the incidence is still low in Africa compared to a developed region like Europe. As seen in the figure below, most African countries have an incidence rate that is less than 50 per 100,000 compared with Western Europe and North America where the rate exceeds 72 and, in the case of Belgium, is over 100.
Despite the lower incidence, an African woman diagnosed with breast cancer has a greater than 50% chance of dying from the disease. In most European countries that figure is considerably lower than 30%. Why is this the case? First, the age at diagnosis is a factor, with the majority of African women presenting at a younger age, before menopause, compared to Europeans who normally present after menopause. Second, the stage of presentation is much later in Africans, when the cancer has often metastasized to other parts of the body. Third, there is the likelihood that gene expression differs between women of African and European ancestry. As explored in a previous blog, the type of cancer may be quite different.
The fourth and probably most important reason in the differing survival rates comes down to management. European women often have ready access to free health care which includes mammographic screening and, once the breast cancer has been diagnosed, treatment options such as breast-conserving surgery, targeted radiotherapy, adjuvant chemotherapy and expensive drugs like Herceptin and Tamoxifen can be offered.
While it may be some time before diagnostic screening tools such as CapeRay’s PantoScanner platform are able to make a difference in the lives of African women, there are some simple steps that the continent’s beleaguered health care providers can take. Known risk factors – such as obesity, physical inactivity and alcohol consumption – should be reduced. And most importantly, women should learn to recognize early signs and symptoms of breast cancer and then have the courage to report to a doctor.